Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kettner

Showing results (751-760 of 809) with videos related to

Pageof 81
Sort By:
Research Square|June 19, 2023
Applying RE-AIM to examine the impact of an implementation facilitation package to scale up a program for Veterans with Chronic Obstructive Pulmonary DiseaseEdward C Portillo, Martha A Maurer, Jordyn T Kettner, et al.
Implementation Science Communications|November 22, 2023
Applying RE-AIM to examine the impact of an implementation facilitation package to scale up a program for Veterans with chronic obstructive pulmonary diseaseEdward C Portillo, Martha A Maurer, Jordyn T Kettner, et al.
Neuropharmacology|December 30, 2022
Canalization and plasticity in psychopathologyR L Carhart-Harris, S Chandaria, D E Erritzoe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 27, 2007
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancerS Boeck, T Hoehler, G Seipelt, et al.
Trials|May 27, 2010
Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)Petr Ostadal, David Alan, Jiri Vejvoda, et al.
The Journal of Manual & Manipulative Therapy|December 17, 2023
Profession-based manual therapy nomenclature: exploring history, limitations, and opportunitiesBrian Degenhardt, Patrick L S van Dun, Eric Jacobson, et al.
Molecular & Cellular Proteomics : MCP|November 26, 2025
Update and new implementation of the MIRAGE reporting guidelines for mass spectrometry experiments in glycoscienceFrederique Lisacek, William E Hackett, Morten Thaysen-Andersen, et al.
Cancer Research|June 29, 2023
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast CancersJuliana Navarro-Yepes, Nicole M Kettner, Xiayu Rao, et al.
Anti-Cancer Drugs|September 23, 2009
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Journal of Critical Care|November 20, 2012
Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: classification tree analysis on data from the Acute Heart Failure Database-Main registryDaniela Tomcikova, Marian Felsoci, Jindrich Spinar, et al.
Pageof 81

Showing results (751-760 of 809) with videos related to

Sort By:
Pageof 81
Research Square|June 19, 2023
Applying RE-AIM to examine the impact of an implementation facilitation package to scale up a program for Veterans with Chronic Obstructive Pulmonary DiseaseEdward C Portillo, Martha A Maurer, Jordyn T Kettner, et al.
Implementation Science Communications|November 22, 2023
Applying RE-AIM to examine the impact of an implementation facilitation package to scale up a program for Veterans with chronic obstructive pulmonary diseaseEdward C Portillo, Martha A Maurer, Jordyn T Kettner, et al.
Neuropharmacology|December 30, 2022
Canalization and plasticity in psychopathologyR L Carhart-Harris, S Chandaria, D E Erritzoe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 27, 2007
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancerS Boeck, T Hoehler, G Seipelt, et al.
Trials|May 27, 2010
Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)Petr Ostadal, David Alan, Jiri Vejvoda, et al.
The Journal of Manual & Manipulative Therapy|December 17, 2023
Profession-based manual therapy nomenclature: exploring history, limitations, and opportunitiesBrian Degenhardt, Patrick L S van Dun, Eric Jacobson, et al.
Molecular & Cellular Proteomics : MCP|November 26, 2025
Update and new implementation of the MIRAGE reporting guidelines for mass spectrometry experiments in glycoscienceFrederique Lisacek, William E Hackett, Morten Thaysen-Andersen, et al.
Cancer Research|June 29, 2023
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast CancersJuliana Navarro-Yepes, Nicole M Kettner, Xiayu Rao, et al.
Anti-Cancer Drugs|September 23, 2009
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'Stefan Boeck, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Journal of Critical Care|November 20, 2012
Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: classification tree analysis on data from the Acute Heart Failure Database-Main registryDaniela Tomcikova, Marian Felsoci, Jindrich Spinar, et al.
Pageof 81